 <h1>Mirabegron Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of mirabegron include:</b> hypertension. <b>Other side effects include:</b> urinary tract infection.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to mirabegron: oral tablet extended release</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, mirabegron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking mirabegron:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>lower back or side pain</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow, fast, or irregular heartbeat</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blindness</li>
<li>decrease in vision</li>
<li>eye pain</li>
<li>lower abdominal or stomach pain</li>
<li>nausea</li>
<li>pain in the groin or genitals</li>
<li>tearing or eyes</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chills</li>
<li>cough</li>
<li>decrease in the frequency of urination</li>
<li>decrease in urine volume</li>
<li>diarrhea</li>
<li>difficulty in passing urine (dribbling)</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of mirabegron may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>body aches or pain</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with breathing</li>
<li>difficulty with moving</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fever</li>
<li>loss of voice</li>
<li>muscle ache or stiffness</li>
<li>sneezing</li>
<li>stomach pain</li>
<li>stuffy or runny nose</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Belching</li>
<li>burning feeling in the chest or stomach</li>
<li>full or bloated feeling</li>
<li>heartburn</li>
<li>hives or welts, skin rash</li>
<li>indigestion</li>
<li>itching or pain of the vagina or genital area</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>pressure in the stomach</li>
<li>redness of the skin</li>
<li>stomach discomfort, upset, or tenderness</li>
<li>swelling of the lips</li>
<li>thick, white vaginal discharge with mild or no odor</li>
</ul><p>
<!-- end oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mirabegron: oral tablet extended release</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.</p><h3>Cardiovascular</h3><p>In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred.  At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (up to 11.3%)</p>
<p><b>Common</b> (1% to 10%): Tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Angioedema of the face, lips, tongue, and/or larynx has been reported.  In some case, this occurred after the first dose or after multiple doses.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash</p>
<p><b>Rare</b> (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, constipation, diarrhea, abdominal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspepsia, gastritis, abdominal distension</p>
<p><b>Rare</b> (less than 0.1%): Lip edema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder.  A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus</p>
<p><b>Postmarketing reports</b>: Urinary retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p>
<p><b>Uncommon</b> (0.1% to 1%): Joint swelling<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, dizziness<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Glaucoma, blurred vision, dry eyes</p>
<p><b>Rare</b> (less than 0.1%): Eyelid edema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Prostate cancer<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased ALT, AST, and GGT<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Confusion, hallucinations, insomnia, anxiety</p><p>The majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL. </p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about mirabegron</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>261 Reviews</li>
<li>Drug class: urinary antispasmodics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mirabegron &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Myrbetriq</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Urinary Frequency</li>
<li>Urinary Incontinence</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mirabegron: oral tablet extended release</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.</p><h3>Cardiovascular</h3><p>In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred.  At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (up to 11.3%)</p><p><b>Common</b> (1% to 10%): Tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Angioedema of the face, lips, tongue, and/or larynx has been reported.  In some case, this occurred after the first dose or after multiple doses.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash</p><p><b>Rare</b> (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, constipation, diarrhea, abdominal pain</p><p><b>Uncommon</b> (0.1% to 1%): Dyspepsia, gastritis, abdominal distension</p><p><b>Rare</b> (less than 0.1%): Lip edema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder.  A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus</p><p><b>Postmarketing reports</b>: Urinary retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia</p><p><b>Uncommon</b> (0.1% to 1%): Joint swelling<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, dizziness<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Glaucoma, blurred vision, dry eyes</p><p><b>Rare</b> (less than 0.1%): Eyelid edema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Rare</b> (less than 0.1%): Prostate cancer<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increased ALT, AST, and GGT<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Postmarketing reports</b>: Confusion, hallucinations, insomnia, anxiety</p><p>The majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.</p><p id="ref_1">1. "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL. </p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about mirabegron</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>261 Reviews</li>
<li>Drug class: urinary antispasmodics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mirabegron &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Urinary Frequency</li>
<li>Urinary Incontinence</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>